ABSTRACT

Virus-like particles (VLPs) derived from human papillomavirus (HPV) L1 capsid proteins were used for HPV quadrivalent recombinant vaccine. The HPV quadrivalent vaccine is administered in a 3-dose regimen of initial injection followed by subsequent doses at 2 and 6 months to prevent cervical cancer, vulvar, and vaginal cancers. The type 6, 11, 16, or 18 of HPV infection is associated with precancerous lesions and genital warts in adolescents and young women. The HPV vaccine is composed of viral L1 capsid proteins are produced in eukaryotic expression systems and purified in the form of VLPs. Four different the L1 protein of 3 different subtypes of HPV: HPV11, HPV16, and HPV18 were expressed in Escherichia coli divided into 2 fragments as N- and C-terminal of each protein in order to examine the efficacy of HPV vaccine. Vaccinated sera failed to recognize N-terminal L1 HPV type 16 and type 18 by western blot while they detected N-terminal L1 protein of HPV type 11. Moreover, the recombinant C-terminal L1 proteins of type 16 was non-specifically recognized by the secondary antibody conjugated with horseradish peroxidase. This expression and purification system may provide simple method to obtain robust recombinant L1 protein of HPV subtypes to improve biochemical analysis of antigens with immunized sera.

Keywords: Papillomaviridae; L1 capsid proteins; Recombinant proteins; Enzyme-linked immunosorbent assay; Western blot

INTRODUCTION

Human papillomavirus (HPV) is a member of the papoviridae virus and consists of a small double-stranded DNA virus containing a circular genome of approximately 8,000 base pairs without an envelope (1). HPV infection is the primary cause of cervical cancer, which can be sexually transmitted (2). The sequence variation on L1 protein, the major element of the viral capsid, encoding gene defines the types of HPV. Over 40 types of different HPVs are
Author Contributions
Data curation: Akuzum B, Hong J, Lee S, Jhun H, Kim S; Formal analysis: Akuzum B, Kim S, Hong J, Lee S, Kim E, Kim J, Choi Y, Jhun H, Lee Y, Kim H, Sohn DH, Kim S; Investigation: Lee S, Kim S; Methodology: Akuzum B, Kim S, Nguyen TT, Kim E, Jhun H, Kim S; Project administration: Kim S; Supervision: Kim S; Validation: Kim S; Writing - original draft: Akuzum B, Kim S; Writing - review & editing: Kim S.

responsible for the anogenital, cervical, and oropharyngeal epithelia infections (3). Low-risk subtypes such as HPV type 6, 11, 42, 43, and 44, lead to warts and condyloma acuminata (genital warts) while the high-risk subtypes such as HPV type 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70, have been shown to be the cause of cervical cancer (4).

HPV type 16 is the cause of about 54% of invasive cervical cancers and HPV type 18 is known for the 17% of worldwide HPV infection (5). Furthermore, HPV type 6 or 11 infections are associated with approximately 90% of all genital warts (6).

HPV expresses 6 early open reading frame (ORF) proteins, E1, E2, E4, E5, E6, and E7 with regulatory functions beside 2 late ORF proteins, major capsid protein L1 and minor capsid protein L2 (7). The self-assemble of major capsid protein L1 into virus-like particles (VLPs) is highly immunogenic (8). L2 protein co-assembles with L1 to form VLPs at the same 1:30 molar ratio as that found in authentic virions (9). Electron photo-micrograph analysis shows that L1 and L1/L2 VLPs cannot be morphologically distinguished from infectious virions, except the lack of electron-dense core that is characteristic of encapsidated viral genome (10).

It was confirmed that after parenteral injection L1 VLPs can induce the high titers of serum antibodies that neutralize bovine papillomavirus type 1 \textit{in vitro} (11) and similar data were obtained with oncogenic HPVs (12-14).

A quadrivalent HPV recombinant vaccine has been developed against HPV types 6, 11, 16, and 18. This vaccine contains the VLPs derived from L1 capsid proteins of HPV type 6, 11, 16, and 18 expressed in \textit{Saccharomyces cerevisiae}. Heterogenic eukaryotic expression systems have recently been employed to generate VLPs (15). The recombinant VLPs proteins have been produced in animal cells (16), insect cells (17), yeast (18), as well as bacterial cells (19) and used the leading candidate vaccines to prevent cervical cancer (20).

HPV competitive radioimmunoassay (cRIA) (21), HPV competitive luminex immunoassay (cLIA) (22), and enzyme-linked immunosorbent assay (ELISA) (23) using VLPs as antigens have been used for quantification of the quadrivalent HPV vaccine. The cLIA assay engages fixing 4 distinct VLPs of HPV type 6b, 11, 16, and 18 to Luminex microspheres with different fluorescent properties (24). The ability of sera samples derived from vaccines to prevent VLP binding is assessed by a type-specific neutralizing monoclonal antibody, which has a phycoerythrin fluorescent tag. For cRIAs HPV type 6b, 11, 16, and 18 L1 VLP antigens coated polystyrene beads are incubated with the compatible HPV type 6b, 11, 16, or 18 specific mouse antibodies (mAbs) and serum sample. \textsuperscript{125}I-tagged goat anti-mouse antibodies were used for detection of mAbs bound on VLPs (25,26). VLP ELISA was developed firstly for HPV type 16 (27), and later this technique has been developed for other HPV types (28). In addition, HPV L1 proteins (type 6b, 16, and 18) fused to glutathione $S$-transferase (GST) was used for GST based ELISA which uses glutathione cross-linked to casein as capture protein to purify and immobilize bacterially expressed GST-L1 (27) fusion proteins as antigens.

Pseudovirion-based (8,29) neutralization assay (PBNA) was used to measure a range of functional neutralizing antibodies although ELISA was used to measure both neutralizing and non-neutralizing antibodies.

The present study demonstrated the production of viral capsid protein L1 of HPV type 11, 16, and 18 expressed in \textit{Escherichia coli} (\textit{E. coli}) as N- and C-terminal proteins. Furthermore, titration assay and western blot techniques with vaccinated and non-vaccinated human sera were used to observe whether there is any reactivity by HPV vaccine.
MATERIALS AND METHODS

Molecular cloning of the HPV L1 protein encoding genes
HPV type 11, 16, and 18 DNA derived from ATCC Company (Manassas, VA, USA) were amplified by PCR, 2 different reaction mixes prepared for each virus type to obtain N- and C-terminal L1 protein fragments. PCR amplified DNA fragments were purified using RBC Bioscience genomic DNA extraction kit (Taipei City, Taiwan). Purified fragments were ligated with pProEx/HTa vector except the C-terminal HPV type 16 coding gene which was ligated with pProEx/HTb vector as described (30-33). After the transformation of the cells into E. coli DH5α strain, the cells were spread on ampicillin (100 µg/ml) containing LB Agar plate and incubated overnight. The colonies harboring ligated constructs were screened by PCR, the plasmid DNAs were purified using plasmid miniprep kit from Cosmo Genetech (Seoul, Korea). The successfully ligated plasmid constructs were sequenced by Cosmo Genetech (Seoul, Korea).

Recombinant N- and C-terminal L1 protein expression and purification
N- and C-terminal L1 protein expressing gene containing DH5α clones were incubated in 10 ml of LB media containing ampicillin (100 µg/ml) at 37°C overnight. The overnight culture was inoculated into 500 ml of LB medium and grown till the cells reach mid-exponential stage (OD value of 0.6–0.7 at A600). The protein expression was induced by adding 0.1 mM of isopropyl β-D-thiogalactopyranoside (IPTG) incubating the cells at 37°C for 4 hours. The induced cells were pelleted down by centrifugation (6,000 rpm, 4°C, for 20 min). After resuspension of the cells in appropriate buffers which were shown in Table 1, suspension was pulse-sonicated at 10 s intervals for 1 min. In the case of urea containing buffers suspensions were incubated at 37°C overnight and of guanidine buffer at 4°C for 4 h.

Following the incubation step sonication was performed one more time. The protein solution was centrifuged at 10,000 rpm for 10 min (for urea buffer at 25°C and for guanidine buffer at 4°C). After the centrifugation the proteins in supernatant was purified with a TALON affinity column (Invitrogen, Carlsbad, CA, USA) using his-6x-tag at the N-terminal of recombinant proteins. The TALON affinity-purified proteins were subjected to high performance liquid chromatography (HPLC) from Agilent Technologies (Santa Clara, CA, USA) as described (34-38).

Serum titration assay
The 96-well immunoplate (SPL Life Sciences, Pocheon, Korea) was coated with successfully purified N- and C-terminal L1 protein of HPV type 11, 16, and 18 (1 µg/ml) and incubated at 4°C overnight. Next day 200 µl of blocking solution (2% bovine serum albumin [BSA] and 0.02% NaN3 in PBS) was added and 96-well plate was incubated at room temperature (RT) for 1 hour. After blocking, the plate was washed with 200 µl of PBS with 0.1% tween

Table 1. The list of lysis buffers was used for protein extraction

| Type of protein | Buffer condition          |
|-----------------|---------------------------|
| N-L1-HPV11      | 50 mM sodium phosphate, 0.3 M NaCl, 8 M urea pH 8.00 |
| N-L1-HPV16      | 20 mM Tris, 8 M urea, 300 mM NaCl pH 8.00          |
| N-L1-HPV18      | 20 mM Tris, 8 M urea, 300 mM NaCl pH 8.00          |
| C-L1-HPV11      | 20 mM Tris, 0.3 M NaCl, 6 M guanidine pH 7.00      |
| C-L1-HPV16      | 50 mM Tris, 0.3 M NaCl, 6 M guanidine pH 8.00      |
| C-L1-HPV18      | 50 mM sodium phosphate, 0.3 M NaCl, 6 M guanidine pH 8.00 |
This study was approved by multiple institutional review board (Seoul, Korea). Vaccinated and non-vaccinated human sera were obtained from healthy individuals that were added on protein coated wells with 1:300, 1:600, and 1:1,200 dilution ratios. Following 2 hours incubation at RT the plate was washed with PBST for 3 times. Goat anti-human IgG conjugated with horseradish peroxidase (HRP) was diluted in PBS and added on wells (100 µl). After incubation at RT for 40 min, the plate was washed with PBST for 3 times then 3′,5′-tetramethylbenzidine (TMB) solution (100 µl) was used for developing (Thermo Scientific, Rockford, IL, USA).

**Western blot analysis**

The SDS-polyacrylamide gel electrophoresis (PAGE) gels were electro-transferred onto nitrocellulose membranes (GE Healthcare, Pittsburgh, PA, USA) for 50 min at 0.3 mA using Bio-Rad transblot apparatus. The membranes were blocked in 5% skim milk in PBST (3.2 mM Na₂HPO₄, 0.5 mM KH₂PO₄, 1.3 mM KCl, 135 mM NaCl, 0.05% Tween-20, pH 7.4) for 20 min at RT. Then the membranes were incubated with human sera (1 to 1,000 dilution in blocking solution) overnight at 4°C. After incubation the membranes were washed with PBST 3 times in a row, each time for 5 min. Goat anti-human IgG HRP conjugate was diluted in blocking solution and membranes were incubated in this mix for 40 min at RT.

**RESULTS**

**Molecular cloning and expression of HPV L1 capsid protein encoding genes**

The N- and C-terminal L1 protein of HPV type 11, 16, and 18 were amplified by PCR from a sample obtained from ATCC Company. The primer sets introduced EcoRI (by forward primer) and XhoI (by reverse primer) restriction sites. After the restriction and purification of PCR amplicon and the vectors pProEx/HTa and pProEx/HTb, N-terminal of all 3 types of HPV, C-terminal L1 protein of HPV type 11 and 18 were cloned into pProEx/HTa and in the case of C-terminal L1 of HPV type 16 into pProEx/HTb. The cloned plasmid DNAs were confirmed both by PCR and DNA sequencing (data not shown).

L1 protein of the HPV species HPV type 11, 16, and 18 were expressed in 2 parts as N- and C-terminal. According to the small-scale expression results N- and C-terminal L1 protein is expressed with higher levels in *E. coli* strain Codon plus or Rosetta comparing to DH5α (Fig. 1), yet expression of HPV type 11 N-terminal L1 protein is expressed highly in DH5α as well. In all cases protein is found in the insoluble fraction.

N- and C-terminal of L1 protein coding sequences were cloned into pProEx/HTa vector and pProEx/HTb in the case of C-L1-HPV type 16. During the large-scale protein production expression was induced by IPTG. After the TALON purification SDS-PAGE was performed and N-terminal L1 protein of HPV type 11 and C-terminal L1 protein of HPV type 16 gels’ Coomassie blue staining results were shown in Fig. 2A and C, yet C-terminal L1 of HPV type 11 and 18 had relatively lower yield, therefore western blotting images were shown (Fig. 2B and D). Moreover, a second band was observed for TALON column purified C-L1-HPV type 16 and 18 on the SDS-PAGE gel. As next step HPLC was performed and the purified proteins were screened by silver staining (Fig. 3). After HPLC small C-L1-HPV type 16 protein fragments appeared on the silver stained gel. Nevertheless, the production of N-terminal L1 protein of HPV type 16 and 18 is failed (data is not shown).
Recognition of L1 Type 11 by HPV Vaccine Immunized Sera

Figure 1. Small scale expression of HPV L1 proteins. C- and N-terminals of HPV-L1 protein were expressed in different E. coli strains: DH5α, Codon+, and Rosetta. The strain with highest protein yield was chosen for further steps. The data represents one of 3 independent experiments.

Figure 2. Expression of HPV L1 proteins in large scale. Large scale expression of (A) N-terminal L1 HPV type 11, (B) C-terminal L1 HPV type 11, (C) C-terminal L1 HPV type 16, and (D) C-terminal L1 HPV type 18. Coomassie blue staining and western blotting results after TALON purification were shown. The data represents 1 of 4 independent experiments.
Titration assay and western blotting to see the antibody response after vaccination

Serum titration assay was performed to see whether there was antibody production against HPV after vaccination, by using non-vaccinated and vaccinated human sera. However, no difference detected between the vaccinated and non-vaccinated samples, except HPV type 11. Both N- and C-terminal HPV type 11 L1 protein showed higher signals with vaccinated human sera comparing to non-vaccinated ones (Fig. 4A). In addition, C-terminal HPV type 16 and 18 showed much higher signals as a result of assays both for vaccinated and non-vaccinated human sera comparing to other antigen types (Fig. 4B).

To investigate if the HPV vaccine Gardasil (Merck, NJ, USA) induces antibody production after appropriate vaccination (3 times), human sera derived from vaccinated and non-vaccinated individuals, and healthy individuals were used for the western blot analysis. Interestingly it has been seen that 2 of the vaccinated human sera out of 4 possessed antibody against N-terminal HPV type 11 (Fig. 5A). Once the 2 sera samples from non-vaccinated humans were compared with sera of same individuals but after vaccination an antibody response against N-terminal L1 HPV type 11 was recognized (Fig. 5B and C).

Moreover C-terminal L1 protein of HPV type was captured in western blot analysis in both cases with vaccinated human sera and non-vaccinated human sera (Fig. 6), yet on the further steps it was shown that binding on the C-terminal L1 protein of HPV type 16 and 18 were non-specific by using the control samples of human sera derived from healthy individuals in both males and females (Fig. 7).

However, one of the samples, which were derived from HPV vaccine injected healthy female, captured N-terminal L1 of HPV type 11 as well. To confirm that C-L1-HPV type 16 and 18 binding was non-specific, western blot was repeated using only secondary antibody, but not human sera and it was reported that the L1 proteins had an interaction with anti-human IgG Fc HRP (Fig. 8).

Figure 3. Further purification and quantitation of recombinant L1 proteins. The first step TALON chromatography purification of HPV-L1 proteins were further purified with HPLC. The purities and concentrations of HPV L1 proteins were examined by silver staining compared to BSA. Each recombinant protein was indicated on the top. The data represents 1 of 4 independent experiments. BSA, bovine serum albumin.
Recognition of L1 Type 11 by HPV Vaccine Immunized Sera

Figure 4. Serum titration of the quadrivalent HPV vaccine. (A) The data was showing the titration assay results using N- or C-terminal L1 protein of HPV type 11 as antigen and (B) showing the results using C-terminal L1 of HPV type 16 or type 18 as antigen. Representative data from 1 of 3 independent experiments are shown. SEM, standard error of mean. Mean SEM (n=7); *p<0.05 from 3 replicates.

Figure 5. Western blot analysis using N-terminal L1 HPV type 11. (A) Western blot was performed by using N-terminal L1 proteins of HPV type 11 with sera of quadrivalent HPV vaccinated individuals as primary sera; (B) non-vaccinated individuals’ sera did not contain antibody against N-terminal L1 protein of HPV type 11; and (C) while N-terminal HPV type 11 was detected by the same individuals’ sera after 3 times injection with the HPV vaccine.
DISCUSSION

We have expressed in E. coli and purified N-terminus L1 protein of HPV type 11 and C-terminus L1 of HPV type 11, 16, and 18. All proteins were insoluble, but because of their different characteristics we used different lysis buffer listed in Table 1 for each of the proteins. As reported by the previous studies the HPV L1 proteins were expressed in bacteria, yet the product was incorrectly folded protein with less immunogenicity than properly assembled particles (29). Since we divided L1 protein as N- and C-terminus, we aimed to overcome this problem. Yet we failed to express the N-terminal L1 protein of HPV type 16 and type 18. This result could be explained by the inhibitor function of N-terminal of HPV16 L1 protein, which has been shown by Ma et al. (39).

By using non-vaccinated, vaccinated and healthy human sera titration assay is performed to examine the antibody forming of vaccine, yet no significant signals are detected, except N-terminal L1 of HPV type 11 as well as C-terminal. To see the reason behind the high signals from the samples using C-terminal L1 HPV type 16 and 18 as antigens, we did further testing with healthy human sera and additionally without sera but the secondary antibody, as a result the binding of these antigens were non-specific.

To support the titration assay carried out with vaccinated and non-vaccinated human sera, we performed western blot. According to the western blot results the vaccinees’ sera comprise antibody against N-terminus L1 protein of HPV type 11. Moreover, after the vaccination of initially not vaccinated individuals, similarly to our previous data, we observed a response to N-terminal L1 of HPV type 11. On the other hand, the C-terminal recombinant proteins of HPV type 16 and 18 bind with anti-human IgG which we used as secondary antibody conjugated with HRP both for ELISA and western blot analysis.

There are several assays to screen antibody responses to HPV, including PBNA, ELISA, cLIA, and the in situ-purified GST L1 fusion protein based ELISA (21-23,40). However, there
is no standardized serological assay available for the evaluation of HPV-specific antibody responses. Although the PBNA is called as golden standard in HPV serology, this assay is highly labor intensive and therefore difficult to apply in large epidemiological studies. The cLIA measures antibodies directed against only one neutralizing epitope for a distinct HPV type, which can result in an underestimation of total neutralizing activity of HPV-specific antibodies. GST-L1 ELISA and VLP-based ELISA measure both antibodies against conformational and linear epitopes, thereby detecting all HPV-specific antibodies. It has been shown that the VLP-based ELISA correlates well with the PBNA (41, 42). Each assay quantifies an overlapping but distinct subset of only HPV type 16/18 VLP antibodies.

Another complication of the quadrivalent HPV vaccine is it only consists of HPV major capsid protein L1 but not the minor L2. As reported by Hernandez et al. (43) HPV L1 VLP and L1-L2 VLP serologic assays to measure virion antibodies to HPV type 16 and 18 simultaneously in a multiplex format were developed. Similar results were observed for both seroassays done with HPV type 16 yet concordance for HPV type 18 was much lower. It is suggested that HPV type 18 L1 VLP seroassay detects non-neutralizing antibodies and cross-reactive antibodies.
while L1–L2 VLP assay detects type-specific neutralizing antibodies. An alternative statement is that L1–L2 capsid is more stable than L1 capsid.

The antibody forming of the quadrivalent HPV vaccine was not sufficient to detect the antigens although the present study was performed with ELISA and western blot with few limited HPV antigens. The experiments were performed using HPV-L1 antigens failed to show the antibody response after vaccination with all the antigens produced. It is necessary to express robust recombinant L1 major capsid protein of all HPV types (6b, 11, 16, and 18) to investigate antigen forming by quadrivalent HPV vaccine. Further study using larger number of samples with biochemical and molecular level of analysis may help to understand specific antibody forming after quadrivalent HPV vaccine.

**ACKNOWLEDGEMENTS**

This paper was supported by Konkuk University in 2017.

**REFERENCES**

1. Favre M. Structural polypeptides of rabbit, bovine, and human papillomaviruses. *J Virol* 1975;15:1239-1247.
2. zur Hausen H. Viruses in human cancers. *Science* 1991;254:1167-1173.
3. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:1157-1164.
4. Burd EM. Human papillomavirus and cervical cancer. *Clin Microbiol Rev* 2003;16:147.

5. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJInternational Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med* 2003;348:518-527.

6. Greer CE, Wheeler CM, Ladner MB, Reutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. *J Clin Microbiol* 1995;33:2058-2063.

7. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. *Br J Cancer* 2003;89:101-105.

8. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet* 2004;364:1757-1765.

9. Volpers C, Schirmacher P, Streeck RE, Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. *Virology* 1994;200:504-512.

10. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. *Mol Med Today* 1999;5:209-215.

11. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. *Proc Natl Acad Sci U S A* 1992;89:12180-12184.

12. Roden RB, Greenstone HL, Kimbauer R, Booy FP, Jessic J, Lowy DR, Schiller JT. In *vitro* generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. *J Virol* 1996;70:5875-5883.

13. Unckell F, Streeck RE, Sapp M. Generation and neutralization of pseudovirions of human papillomavirus type 33. *J Virol* 1997;71:2934-2939.

14. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In *vitro* infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. *J Virol* 1998;72:959-964.

15. Doorbar J, Gallimore PH. Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. *J Virol* 1987;61:2793-2799.

16. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. *Virology* 1991;185:251-257.

17. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in *vivo* and in *vitro* assembly of viruslike particles. *J Virol* 1993;67:1936-1944.

18. Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L, Tommasino M. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. *Virology* 1995;206:126-135.

19. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Krahenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated *Salmonella typhimurium* elicit mucosal and systemic neutralizing antibodies in mice. *Infect Immun* 1997;65:3328-3336.

20. Cho HJ, Shin HJ, Han IK, Jung WW, Kim YB, Sul D, Oh YK. Induction of mucosal and systemic immune responses following oral immunization of mice with *Lactococcus lactis* expressing human papillomavirus type 16 L1. *Vaccine* 2007;25:8049-8057.

21. Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, Joyce JG, Jansen KU. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. *Vaccine* 2001;19:3733-3743.
22. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. *Clin Diagn Lab Immunol* 2005;12:959-969.

23. Kimbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. *J Natl Cancer Inst* 1994;86:494-499.

24. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. *Clin Diagn Lab Immunol* 2003;10:108-115.

25. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. *Virology* 1996;223:174-184.

26. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. *Virology* 1996;224:477-486.

27. Sehr P, Müller M, Höpf R, Widschwendter A, Pawlita M. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. *J Virol Methods* 2002;106:61-70.

28. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006;367:1247-1255.

29. Zhang W, Carmichael J, Ferguson J, Inglis S, Ashrafian H, Stanley M. Expression of human papillomavirus type 16 L1 protein in *Escherichia coli*: denaturation, renaturation, and self-assembly of virus-like particles in vitro. *Virology* 1998;243:423-431.

30. Lee S, Choi DK, Kwak A, Kim S, Nguyen TT, Gil G, Kim E, Yoo KH, Kim IA, Lee Y, et al. IL-32-induced inflammatory cytokines are selectively suppressed by α1-antitrypsin in mouse bone marrow cells. *Immune Netw* 2017;17:116-120.

31. Lee S, Kim E, Jhun H, Kim J, Park U, Jo S, Kwak A, Kim S, Nguyen TT, Kang Y, Choi I, et al. Species specific antiviral activity of porcine interferon-α (IFNα). *Immune Netw* 2017;17:424-436.
38. Bae S, Kang T, Hong J, Lee S, Choi J, Jhun H, Kwak A, Hong K, Kim E, Jo S, et al. The contradictory functions (activation/termination) of neutrophil proteinase 3 (PR3) in IL-33 biological activity. *J Biol Chem* 2012;287:8205-8213.

39. Ma Z, Chen B, Zhang F, Yu M, Liu T, Liu L. Increasing the expression levels of papillomavirus major capsid protein in *Escherichia coli* by N-terminal deletion. *Protein Expr Purif* 2007;56:72-79.

40. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. *Clin Chem* 2005;51:1845-1853.

41. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirus-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. *Hum Vaccin* 2008;4:425-434.

42. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. *Hum Vaccin* 2009;5:705-719.

43. Hernandez BY, Ton T, Shvetsov YB, Goodman MT, Zhu X. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies. *Clin Vaccine Immunol* 2012;19:1348-1352.